{
    "organizations": [],
    "uuid": "2d241989a0a7117b2924a5bb1e2d4ab67f968cc9",
    "author": "Noemie Bisserbe",
    "url": "https://www.wsj.com/articles/sanofi-to-pay-4-85-billion-for-biotech-focused-on-small-antibodies-1517221477",
    "ord_in_thread": 0,
    "title": "Sanofi to Pay $4.85 Billion for Biotech Focused on Small Antibodies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "PARIS—Sanofi SA said Monday it would buy Belgian biotech Ablynx NV for €3.9 billion ($4.85 billion), the French drugmaker’s second acquisition this month after purchasing U.S. hemophilia specialist Bioverativ Inc.\nSanofi will pay €45 a share for Ablynx, which earlier this month rejected a €2.6 billion offer from Denmark’s Novo Nordisk A/S. Novo Nordisk said Monday it won’t be making a revised proposal.\nThe... To Read the Full Story Subscribe Sign In",
    "published": "2018-01-29T13:24:00.000+02:00",
    "crawled": "2018-01-30T00:43:30.034+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "sa",
        "said",
        "monday",
        "would",
        "buy",
        "belgian",
        "biotech",
        "ablynx",
        "nv",
        "billion",
        "billion",
        "french",
        "drugmaker",
        "second",
        "acquisition",
        "month",
        "purchasing",
        "hemophilia",
        "specialist",
        "bioverativ",
        "sanofi",
        "pay",
        "share",
        "ablynx",
        "earlier",
        "month",
        "rejected",
        "billion",
        "offer",
        "denmark",
        "novo",
        "nordisk",
        "novo",
        "nordisk",
        "said",
        "monday",
        "making",
        "revised",
        "proposal",
        "read",
        "full",
        "story",
        "subscribe",
        "sign"
    ]
}